Table 1 Relationship between HMGB1 expression and clinicopathologic features in a validated cohort
Clinicopathologic features | Low expression, n = 18 (%) | High expression, n = 18 (%) | P-value |
|---|---|---|---|
Age (years) | |||
  < 45 | 9 (50%) | 10 (55.6%) | P = 0.738 |
  ≥ 45 | 9 (50%) | 8 (44.4%) |  |
Gender | |||
 Male | 7 (66.7%) | 8 (22.2%) | P = 0.597 |
 Female | 11 (33.3%) | 10 (77.8%) |  |
Tumor size (cm) | |||
  < 1 | 12 (66.7%) | 6 (33.3%) | P = 0.046 |
  ≥ 1 | 6 (33.3%) | 12 (66.7%) |  |
Lymph node metastasis | |||
 No | 13 (72.2%) | 6 (33.3%) | P = 0.019 |
 Yes | 5 (27.8%) | 12 (66.7%) |  |
Histological type | |||
 PTC | 9 (50%) | 10 (55.6%) | P = 0.738 |
 FTC | 9 (50%) | 8 (44.4%) |  |
Clinical stage | |||
 I + II | 13 (72.2%) | 7 (38.9%) | P = 0.044 |
 III + IV | 5 (27.8%) | 11 (61.1%) |  |